Correction to: Cell Discovery (2021) 7:119
https://doi.org/10.1038/s41421-021-00357-z published online 14 December 2021
In the original publication of this article1, we made some mistakes in Fig. 4c and d. The layer of nucleus was missing in the images of CK5 and CK8 of Fig. 4c, and the layer of Ace2 was shifted in the image of Ace2 of Fig. 4d. The correctly labelled Fig. 4c and d are displayed as below. This correction does not affect the results or the conclusion of this work.
Reference
Wang, J. et al. SARS-CoV-2 uses metabotropic glutamate receptor subtype 2 as an internalization factor to infect cells. Cell Discov. 7, 119 (2021).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, J., Yang, G., Wang, X. et al. Author Correction: SARS-CoV-2 uses metabotropic glutamate receptor subtype 2 as an internalization factor to infect cells. Cell Discov 7, 124 (2021). https://doi.org/10.1038/s41421-021-00365-z
Published:
Version of record:
DOI: https://doi.org/10.1038/s41421-021-00365-z
This article is cited by
-
Claudin-11 plays a pivotal role in the clathrin-mediated endocytosis of influenza A virus
Science China Life Sciences (2025)
